Compare Alliant Energy Corporation (LNT) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alliant Energy Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? Alliant Energy Corporation trades at $68.56 (market cap $17.78B), while Vertex Pharmaceuticals Incorporated trades at $529.62 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 7.6× Alliant Energy Corporation's market cap, and Alliant Energy Corporation pays a 3.12% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| LNT | VRTX | |
|---|---|---|
Market Cap | $17.78B | $134.25B |
Sector | Utilities | Health |
52-Week High | $78.03 | $529.65 |
52-Week Low | $63.62 | $376.62 |
Enterprise Value | $29.88B | $128.37B |
Dividend Yield | 3.12% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
